Confirmed antiviral effect of Kowa ivermectin on "Omicron strain"
PRESS RELEASE
January 31, 2022
To everyone
Kowa Co., Ltd. (hereinafter referred to as "Kowa") has announced that the investigational drug "ivermectin" used in Phase III clinical trials (development code: K-237) for the treatment of new coronavirus (SARS-CoV-2) infection From a joint research (non-clinical trial) with Kitasato University, it was confirmed that the same antiviral effect is applied to the Omicron strain as well as the existing mutant strain (alpha beta gamma delta strain). ..
As announced in July 2021, Kowa directly from Professor Satoshi Omura, a special honorary professor at Kitasato University, who won the Nobel Prize in Physiology or Medicine, about conducting clinical trials of ivermectin as a therapeutic drug for new coronavirus infections. I received a request. We believe that it is the mission of pharmaceutical companies to contribute to the treatment of new coronavirus infections and protect the health of the people, and conduct clinical trials to confirm the efficacy and safety of ivermectin against new coronavirus infections. doing.
Ivermectin has been distributed by WHO to infected areas for over 30 years as a treatment for parasitic infections. Especially in some African countries, it has been confirmed to be safe enough for volunteers to distribute directly to people. In addition, ivermectin has been reported to suppress the invasion of SARS-CoV-2 into cells and inhibit replication, and is expected to be applied as a new coronavirus infection therapeutic drug (tablet) for drug repositioning. .. In this clinical trial, the dosage and administration are different from those already approved for the treatment of parasitic infections, but the efficacy and safety are being confirmed in the clinical trial.
Kowa will contribute to the treatment of new coronavirus infections by confirming the clinical effect of ivermectin on SARS-CoV-2 and providing it to the public as soon as possible.
Overseas, it was reported that patients use high-content ivermectin for animals, which is dangerous for humans, and adverse events occur. (Good Clinical Practice) ”is conducting clinical trials of ivermectin in accordance with strict standards.
That's all
Public Relations Department (Tokyo) 3-4-14 Nihonbashihoncho, Chuo-ku, Tokyo
TEL: 03-3279-7392
Main store (Nagoya) 3-6-29 Nishiki, Naka-ku, Nagoya
You must include www
Links to PDF
Original
https://www.kowa.co.jp/news/2022/press220131.pdf
Archived (JP text):
https://files.catbox.moe/wtidbt.pdf
Content
Japanese Text:
興和 イベルメクチンの「オミクロン株」への抗ウイルス効果を確認
PRESS RELEASE
2022 年 1 月 31 日
各 位
興和株式会社(以下、「興和」)は、新型コロナウイルス(SARS-CoV-2)感染 治療に対する第Ⅲ相臨床試験(開発コード:K-237)で使用している治験薬「イベルメクチン」につきまして、北里大学との共同研究(非臨床試験)から、既存の変異株(アルファ・ベータ・ガンマ・デルタ株)と同様に、オミクロン株に対しても同等の抗ウイルス効果があることを確認いたしました。
興和は 2021 年 7 月に発表したとおり、ノーベル生理学医学賞受賞の大村智北里大学特別栄誉教授から直接、新型コロナウイルス感染症を対象とした、治療薬としてのイベルメクチンの臨床試験実施についてご依頼を受けました。新型コロナウイルス感染症治療に少しでも貢献し、国民の健康を守っていくことが製薬会社の使命と考え、イベルメクチンの新型コロナウイルス感染症に対する有効性ならびに安全性を確認するための臨床試験を実施しています。
イベルメクチンは寄生虫感染症治療薬として、WHO が感染地域に 30 年以上にわたって配布しています。特にアフリカの一部の国では、ボランティアが人々に直接配布するほどの安全性が確認されています。また、イベルメクチンは SARS-CoV-2 の細胞内への侵入抑制と複製阻害という作用が報告されており、ドラッグリポジショニングとしての新型コロナウイルス感染症治療薬(錠剤)としての応用が期待されています。なお、本臨床試験では、寄生虫感染症治療薬としてすでに承認されている用法・用量と異なっていますが、臨床試験の中で有効性・安全性を確認しているところです。
興和はイベルメクチンの SARS-CoV-2 に対する臨床効果を確認し、いち早く国民の皆様に提供することで、新型コロナウイルス感染症治療に少しでも貢献してまいります。
※海外において、患者さんがヒトには危険な高含量の動物用イベルメクチンを使用し、有害事象が発現するとの報道がありましたが、興和は、ヒトに対する医薬品の臨床試験の実施基準である「GCP(Good Clinical Practice)」で定められている厳格な基準に則り、イベルメクチンの臨床試験を実施しています。
以 上
広報部(東京) 東京都中央区日本橋本町 3-4-14
TEL:03-3279-7392
本店(名古屋) 名古屋市中区錦 3-6-29
English (Google Machine Translation, Unedited)
Confirmed antiviral effect of Kowa ivermectin on "Omicron strain"
PRESS RELEASE
January 31, 2022
To everyone
Kowa Co., Ltd. (hereinafter referred to as "Kowa") has announced that the investigational drug "ivermectin" used in Phase III clinical trials (development code: K-237) for the treatment of new coronavirus (SARS-CoV-2) infection From a joint research (non-clinical trial) with Kitasato University, it was confirmed that the same antiviral effect is applied to the Omicron strain as well as the existing mutant strain (alpha beta gamma delta strain). ..
As announced in July 2021, Kowa directly from Professor Satoshi Omura, a special honorary professor at Kitasato University, who won the Nobel Prize in Physiology or Medicine, about conducting clinical trials of ivermectin as a therapeutic drug for new coronavirus infections. I received a request. We believe that it is the mission of pharmaceutical companies to contribute to the treatment of new coronavirus infections and protect the health of the people, and conduct clinical trials to confirm the efficacy and safety of ivermectin against new coronavirus infections. doing.
Ivermectin has been distributed by WHO to infected areas for over 30 years as a treatment for parasitic infections. Especially in some African countries, it has been confirmed to be safe enough for volunteers to distribute directly to people. In addition, ivermectin has been reported to suppress the invasion of SARS-CoV-2 into cells and inhibit replication, and is expected to be applied as a new coronavirus infection therapeutic drug (tablet) for drug repositioning. .. In this clinical trial, the dosage and administration are different from those already approved for the treatment of parasitic infections, but the efficacy and safety are being confirmed in the clinical trial.
Kowa will contribute to the treatment of new coronavirus infections by confirming the clinical effect of ivermectin on SARS-CoV-2 and providing it to the public as soon as possible.
That's all
Public Relations Department (Tokyo) 3-4-14 Nihonbashihoncho, Chuo-ku, Tokyo
TEL: 03-3279-7392
Main store (Nagoya) 3-6-29 Nishiki, Naka-ku, Nagoya
English translation from EchoLight:
https://files.catbox.moe/696met.pdf
https://kowa.co.jp/news/2022/press220131.pdf
You must include www
https://www.kowa.co.jp/news/2022/press220131.pdf
Archived (JP text):
https://files.catbox.moe/wtidbt.pdf
Link doesn't load for me. 😕
Same, even when I use an Japanese VPN.
u/TCPatriot The URL is missing www
https://www.kowa.co.jp/news/2022/press220131.pdf
Archived (JP text):
https://files.catbox.moe/wtidbt.pdf
Nihongo-o naratte imasu .... wakarimasen. :-(